Related Experiment Video
Updated: Jan 25, 2026
Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
Published on: May 12, 2023
Recent advances in bispecific antibody-drug conjugates for breast cancer therapy
Xuan Ji1, Yalong Yang1, Cong Ma1
1Breast Cancer Center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, National Clinical Research Center for Cancer, Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan Clinical Research Center for Breast Cancer, No.116 Zhuo Daoquan South Road, Wuhan, 430079, Hubei, China.
Purpose:
Bispecific antibody-drug conjugates (BsADCs) represent a promising strategy to overcome limitations of conventional ADCs in breast cancer, such as tumor heterogeneity and inefficient internalization. This review summarizes recent advances and the therapeutic potential of BsADCs.
Methods:
We conducted a literature review, focusing on BsADC candidates selected for clinical relevance (e.g., ZW49, BL-B01D1), mechanistic innovation (e.g., biparatopic targeting, engaging fast-internalizing receptors), and potential in challenging subtypes like triple-negative breast cancer (TNBC).
Results:
BsADCs enhance drug delivery through dual targeting. Biparatopic HER2-targeting agents (e.g., ZW49, JSKN003) induce receptor clustering and robust internalization. BsADCs co-engaging rapidly internalizing receptors (e.g., HER2×CD63) hijack efficient endocytic pathways, showing activity even in low HER2-expression models. Furthermore, BsADCs targeting compensatory pathways, such as EGFR×HER3 (BL-B01D1) and TROP2×HER3 (JSKN016), have demonstrated breakthrough efficacy in TNBC. Optimization of linker technology and drug-to-antibody ratio (DAR) has improved stability and the therapeutic window, enabling the progression of several BsADCs into Phase III trials.
Conclusion:
BsADCs are a transformative therapeutic modality for breast cancer. Their ability to enhance tumor selectivity, overcome heterogeneity, and target resistant pathways positions them as key players in the future oncology landscape, with ongoing trials poised to define their clinical role.
Insights
Bispecific antibody-drug conjugates (BsADCs) offer a novel approach to breast cancer treatment by improving drug delivery and overcoming resistance. These advanced therapies show significant promise, particularly in challenging subtypes like triple-negative breast cancer (TNBC).
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- Conventional antibody-drug conjugates (ADCs) face limitations in breast cancer treatment due to tumor heterogeneity and inefficient cellular uptake.
- Bispecific antibody-drug conjugates (BsADCs) are emerging as a superior strategy to address these challenges.
Purpose of the Study:
- To review recent advancements in BsADCs for breast cancer therapy.
- To evaluate the therapeutic potential of BsADCs, focusing on mechanistic innovations and clinical relevance.
Main Methods:
- Literature review of BsADC candidates with clinical relevance (e.g., ZW49, BL-B01D1).
- Focus on mechanistic innovations like biparatopic targeting and engagement of fast-internalizing receptors.
- Assessment of BsADC potential in challenging subtypes, including triple-negative breast cancer (TNBC).
Main Results:
- BsADCs enhance drug delivery via dual targeting, promoting receptor clustering and internalization (e.g., biparatopic HER2 agents).
- Co-engagement of rapidly internalizing receptors (e.g., HER2×CD63) improves efficacy, even in low HER2-expression models.
- Targeting compensatory pathways (e.g., EGFR×HER3, TROP2×HER3) shows breakthrough efficacy in TNBC.
- Optimized linker technology and drug-to-antibody ratio (DAR) improve stability and therapeutic window, advancing BsADCs to Phase III trials.
Conclusions:
- BsADCs represent a transformative therapeutic modality for breast cancer.
- Their enhanced tumor selectivity, ability to overcome heterogeneity, and capacity to target resistant pathways position them as key future oncology agents.
- Ongoing clinical trials are expected to define the definitive role of BsADCs in breast cancer treatment.
Related Concept Videos
01:28Drug Therapy
Antianxiety Medications
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Conjugated Proteins
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
01:26Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications